# EDGAR Filing Document

**Accession Number:** 0001597264
**File Stem:** 0001558370-25-008742
**Filing Date:** 2025-6
**Character Count:** 6272
**Document Hash:** 0ceab5c1207a58ae5504fec92ae10100
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001558370-25-008742.hdr.sgml**: 20250620

**ACCESSION NUMBER**: 0001558370-25-008742

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20250618

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20250620

**DATE AS OF CHANGE**: 20250620

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Blueprint Medicines Corp
- **CENTRAL INDEX KEY:** 0001597264
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37359
- **FILM NUMBER:** 251059134

**BUSINESS ADDRESS:**
- **STREET 1:** 45 SIDNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-374-7580

**MAIL ADDRESS:**
- **STREET 1:** 45 SIDNEY STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934**

Date of Report (Date of Earliest Event Reported): **June 18, 2025** 

**Blueprint Medicines Corporation**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37359** | **26-3632015** |
| (State or other jurisdiction <br>of incorporation) | (Commission File Number) | (I.R.S. Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **45 Sidney Street**<br>**Cambridge, Massachusetts** | **02139** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(617) 374-7580**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Exchange Act:

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;Title of each class | &nbsp;&nbsp;Trading symbol(s) | &nbsp;&nbsp;Name of each exchange on which registered |
| &nbsp;&nbsp;Common stock, par value $0.001 per share | &nbsp;&nbsp;BPMC | &nbsp;&nbsp;Nasdaq Global Select Market |

---

**Item 5.07. Submission of Matters to a Vote of Security Holders.** 

Blueprint Medicines Corporation (the "Company") held its Annual Meeting of Stockholders on June 18, 2025. The following is a summary of the matters voted on at that meeting:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. The Company's stockholders elected Jeffrey W. Albers, Mark Goldberg, M.D. and John Tsai, M.D. as Class I directors, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until their successor has been duly elected and qualified. The results of the stockholders' vote with respect to the election of such Class I directors were as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name** | &nbsp;&nbsp;**VotesFor** | &nbsp;&nbsp;**VotesWithheld** | &nbsp;&nbsp;**BrokerNon-Votes** |
| &nbsp;&nbsp;Jeffery W. Albers | &nbsp;&nbsp;44683223 | &nbsp;&nbsp;15507415 | &nbsp;&nbsp;2342656 |
| &nbsp;&nbsp;Mark Goldberg, M.D. | &nbsp;&nbsp;46734594 | &nbsp;&nbsp;13456044 | &nbsp;&nbsp;2342656 |
| &nbsp;&nbsp;John Tsai, M.D. | &nbsp;&nbsp;47572890 | &nbsp;&nbsp;12617748 | &nbsp;&nbsp;2342656 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. The Company's stockholders approved the non-binding, advisory vote on the compensation paid to its named executive officers. The results of the stockholders' non-binding, advisory vote with respect to compensation paid to the Company's named executive officers were as follows :

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**VotesFor** | &nbsp;&nbsp;**VotesAgainst** | &nbsp;&nbsp;**VotesAbstaining** | &nbsp;&nbsp;**BrokerNon-Votes** |
| &nbsp;&nbsp;57714069 | &nbsp;&nbsp;2450825 | &nbsp;&nbsp;25744 | &nbsp;&nbsp;2342656 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting for the fiscal year ending December 31, 2025. The results of the stockholders' vote with respect to such ratification were as follows :

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;**VotesFor** | &nbsp;&nbsp;**VotesAgainst** | &nbsp;&nbsp;**VotesAbstaining** |
| &nbsp;&nbsp;62209853 | &nbsp;&nbsp;288580 | &nbsp;&nbsp;34861 |

---

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **BLUEPRINT MEDICINES CORPORATION** | **BLUEPRINT MEDICINES CORPORATION** |
| Date: June 20, 2025  | By: | /s/ Kathryn Haviland |
|  |  | Kathryn Haviland |
|  |  | Chief Executive Officer |

---